Immunoadsorption therapy for dilated cardiomyopathy using tryptophan column—A prospective, multicenter, randomized, within-patient and parallel-group comparative study to evaluate efficacy and safety

Journal of Clinical Apheresis

Volumn 31, Issue 6, 2016, Pages 535-544

  Yoshikawa, Tsutomu ^a   Baba, Akiyasu ^b   Akaishi, Makoto ^b   Wakabayashi, Yasuhisa ^b   Monkawa, Toshiaki ^c   Kitakaze, Masafumi ^d   Izumi, Tohru ^e   Tomoike, Hitonobu ^a  

^a SAKAKIBARA HEART INSTITUTE   (Japan)

^b KITASATO INSTITUTE HOSPITAL   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^e KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

antibodies; dilated cardiomyopathy; heart failure; immune system

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; AUTOANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; TRYPTOPHAN;

ADULT; ANTIBODY TITER; ARTICLE; CARDIOTHORACIC RATIO; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; IMMUNOADSORPTION; JAPAN; LABORATORY DEVICE; MALE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT SAFETY; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRYPTOPHAN COLUMN; BLOOD; CARDIOMYOPATHY, DILATED; CLINICAL TRIAL; EXERCISE; HEART STROKE VOLUME; OXYGEN CONSUMPTION; PHYSIOLOGY; STANDARDS; TREATMENT OUTCOME;

AUTOANTIBODIES; CARDIOMYOPATHY, DILATED; EXERCISE; HUMANS; IMMUNOSORBENT TECHNIQUES; OXYGEN CONSUMPTION; PATIENT SAFETY; PROSPECTIVE STUDIES; QUALITY OF LIFE; STROKE VOLUME; TREATMENT OUTCOME; TRYPTOPHAN;

EID: 84958191359     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21446     Document Type: Article

References (28)

1. Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ Res 1989; 64:97–103.
2. Baba A, Yoshikawa T, Chino M, Murayama A, Mitani K, Nakagawa S, Fujii I, Shimada M, Akaishi M, Iwanaga S, Asakura Y, Fukuda K, Mitamura H, Ogawa S. Characterization of anti-myocardial autoantibodies in Japanese patients with dilated cardiomyopathy. Jpn Circ J 2001; 65:867–873.
3. Lauer B, Schanwell M, Kühl U, Strauer BE, Schultheiss HP. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000; 35:11–18.
4. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, Ishida M, Hiai H, Matsumori A, Minato N, Honjo T. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003; 9:1477–1483.
5. Baba A, Yoshikawa T, Fukuda Y, Sugiyama T, Shimada M, Akaishi M, Tsuchimoto K, Ogawa S, Fu M. Autoantibodies against M2-muscarinic acetylcholine receptors: new upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J 2004; 25:1108–1115.
6. Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, Wainai Y, Takahashi T, Ogawa S. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res 2001; 88:578–586.
7. Fukuda Y, Miyoshi S, Tanimoto K, Oota K, Fujikura K, Iwata M, Baba A, Hagiwara Y, Yoshikawa T, Mitamura H, Ogawa S. Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits. J Am Coll Cardiol 2004; 43:1090–1100.
8. Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001; 37:418–424.
9. Müller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, Nissen E, Kunze R, Hetzer R. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101:385–391.
10. Dandel M, Wallukat G, Englert A, Lehmkuhl HB, Knosalla C, Hetzer R. Long-term benefits of immunoadsorption in β(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur J Heart Fail 2012; 14:1374–1388.
11. Ameling S, Herda LR, Hammer E, Steil L, Teumer A, Trimpert C, Dörr M, Kroemer HK, Klingel K, Kandolf R, Völker U, Felix SB. Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy. Eur Heart J 2013; 34:666–675.
12. Reinthaler M, Empen K, Herda LR, Schwabe A, Rühl M, Dörr M, Felix SB. The effect of a repeated immunoadsorption in patients with dilated cardiomyopathy after recurrence of severe heart failure symptoms. J Clin Apher 2015; 30:217–223.
13. Staudt A, Böhm M, Knebel F, Grosse Y, Bischoff C, Hummel A, Dahm JB, Borges A, Jochmann N, Wernecke KD, Wallukat G, Baumann G, Felix SB. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002; 106:2448–2453.
14. Baba A, Akaishi M, Shimada M, Monkawa T, Wakabayashi Y, Takahashi M, Nagatomo Y, Yoshikawa T. Complete elimination of cardiodepressant IgG3 autoantibodies by immunoadsorption in patients with severe heart failure. Circ J 2010; 74:1372–1377.
15. Staudt A, Dörr M, Staudt Y, Böhm M, Probst M, Empen K, Plötz S, Maschke HE, Hummel A, Baumann G, Felix SB. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: Results from protein A immunoadsorption. Am Heart J 2005; 150:729–736.
16. Nagatomo Y, Baba A, Ito H, Naito K, Yoshizawa A, Kurita Y, Nakamura I, Matsubara T, Wakabayashi Y, Ogawa S, Akaishi M, Yoshikawa T. Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy. J Clin Apher 2011; 26:1–8.
17. JCS Joint Working Group. Guidelines for diagnosis and treatment of myocarditis (JCS 2009): digest version. Circ J 2011; 75:734–743.
18. Tsuboi Y, Takahashi M, Ishikawa Y, Okada H, Yamada T. Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. Ther Apher 1998; 2:297–299.
19. Sasayama S, Asanoi H, Ishizaka S. Evaluation of functional capacity of patients with congestive heart failure. Yasuda H, Kawaguchi H, editors. New Aspects in the Treatment of Failing Heart. Berlin: Springer, 1992; 113–117.
20. de Groote P, Delour P, Mouquet F, Lamblin N, Dagorn J, Hennebert O, Le Tourneau T, Foucher-Hossein C, Verkindére C, Bautners C. The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. Am Heart J 2007; 154:589–595.
21. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83:778–786.
22. Williams KA, Bryant TA, Taillon LA. First-pass radionuclide angiographic analysis with two regions of interest to improve left ventricular ejection fraction accuracy. J Nucl Med 1998; 39:1857–1861.
23. Grönefeld GC, Hohnloser SH. Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications. J Cardiovasc Pharmacol Ther 2003; 8:107–113.
24. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamura M, Ikeda H, Sakai M. Cytokine adsorptive property of various adsorbents in immunoadsorption columns and a newly developed adsorbent: an in vitro study. Blood Purif 2004; 22:530–536.
25. Baba A, Yoshikawa T, Ogawa S. Autoantibodies produced against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 40:1153–1159.
26. Mobini R, Staudt A, Felix SB, Baumann G, Wallukat G, Deinum J, Svensson H, Hjalmarson A, Fu M. Hemodynamic improvement and removal of autoantibodies against β1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 2003; 20:345–350.
27. Mulder AH, Stegeman CA, Kallenberg CG. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: A predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol 1995; 101:227–232.
28. Warraich RS, Noutsias M, Kazak I, Seeberg B, Dunn MJ, Schultheiss HP, Yacoub MH, Kuhl U. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: Immunoglobulin G3 and clinical correlates. Am Heart J 2002; 143:1076–1084.